GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Total Receivables

ANL (Adlai Nortye) Total Receivables : $2.30 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Total Receivables?

Adlai Nortye's Total Receivables for the quarter that ended in Jun. 2024 was $2.30 Mil.


Adlai Nortye Total Receivables Historical Data

The historical data trend for Adlai Nortye's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Total Receivables Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Total Receivables
1.93 0.35 0.36

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Total Receivables Get a 7-Day Free Trial 0.35 0.46 0.59 0.36 2.30

Adlai Nortye Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Adlai Nortye Total Receivables Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Adlai Nortye Business Description

Traded in Other Exchanges
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.